AKBA(Akebia Therapeutics, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $211.65M | $292.48M | $194.62M | $160.18M | $236.20M |
| 毛利润 | $60.98M | $206.92M | $120.47M | $97.00M | $196.73M |
| 营业利润 | −$264.50M | −$80.78M | −$46.26M | −$50.47M | $23.50M |
| 净利润 | −$282.02M | −$94.23M | −$51.92M | −$69.41M | −$5.34M |
| 经营现金流 | −$252.97M | −$73.15M | −$23.38M | −$40.66M | $67.99M |
| 自由现金流 | −$253.02M | −$73.27M | −$23.38M | −$40.69M | $67.70M |
| 摊薄每股收益 | $-1.70 | $-0.52 | $-0.28 | $-0.33 | $-0.02 |